0
selected
-
1.
Effect of early time-restricted feeding on the metabolic profile of adults with excess weight: A systematic review with meta-analysis.
Pureza, IROM, Macena, ML, da Silva Junior, AE, Praxedes, DRS, Vasconcelos, LGL, Bueno, NB
Clinical nutrition (Edinburgh, Scotland). 2021;(4):1788-1799
Abstract
BACKGROUND & AIMS Time-restricted feeding (TRF) studies have been summarized in previous systematic reviews, but these were not specific for individuals with excess weight and studies involving early time-restricted feeding (eTRF). This meta-analysis aimed to evaluate the effect of eTRF on the metabolic profile of adults with excess weight. METHODS Data were extracted from MEDLINE, CENTRAL, LILACS, Web of Science, ClinicalTrials.gov, OpenGrey.eu, Greylit, and by manual search. Randomized controlled trials in which the participants were older than 18 years, with a body mass index greater than 25 kg/m2 and that were allocated in an intervention with eTRF were included. The studies should have assessed any of the following outcomes from the metabolic profile: resting metabolic rate, triacylglycerol, total cholesterol, HDL-cholesterol, and LDL-cholesterol, fasting blood glucose, insulin, HOMA-IR, C-reactive protein, Interleukin-6, cortisol, leptin, Ghrelin, Peptide YY and glucagon-like peptide, hemodynamic parameters, and appetite. The risk of bias was assessed using the Cochrane collaboration tool. Publication bias was examined with a funnel plot and Egger's test. GRADE was used to assess the overall quality of evidence. RESULTS Ten articles from nine randomized clinical trials, with 264 individuals, were included in qualitative analysis and eight articles with 184 individuals were included in the meta-analysis. There were significant effects on the fasting blood glucose (WMD: -2.75; 95% CI [-4.59; -0.90] mg/dL; p < 0.01; I2 = 88.7%; 7 studies) and HOMA-IR. (WMD: -0.50; 95% CI [-0.82; -0.19]; p < 0.01; I2 = 50.8%; 4 studies). The other outcomes were not significant. Three studies showed a high risk of bias. Seven outcomes were classified as very low quality and one as low quality. There was evidence of publication bias for fasting blood glucose. CONCLUSIONS Although the eTRF regimen seems to have a beneficial effect on the fasting blood glucose and HOMA-IR of individuals with excess weight, the results of this meta-analysis should be analyzed with caution due to the low-quality evidence.
-
2.
A systematic review and meta-analysis: The effects of probiotic supplementation on metabolic profile in patients with neurological disorders.
Tamtaji, OR, Milajerdi, A, Reiner, Ž, Asemi, Z, Dadgostar, E, Heidari-Soureshjani, R, Mamsharifi, P, Amirani, E, Mirzaei, H, Hallajzadeh, J, et al
Complementary therapies in medicine. 2020;:102507
Abstract
BACKGROUND AND OBJECTIVE The objective of meta-analysis of randomized controlled trials (RCTs) was to evaluate the effects of probiotic supplementation on metabolic status in patients with neurological disorders. METHODS The following databases were search up to April 2019: Pubmed, Scopus, Google scholar, Web of Science, and Cochrane Central Register of Controlled Trials. The quality of the relevant extracted data was assessed according to the Cochrane risk of bias tool. Data were pooled by the use of the inverse variance method and expressed as mean difference with 95 % Confidence Intervals (95 % CI). RESULTS Nine studies were included in this meta-analysis. The findings suggested that probiotic supplementation resulted in a significant reduction in C-reactive protein (CRP) [Weighted Mean Difference (WMD): -1.06; 95 % CI: -1.80, -0.32] and malondialdehyde (MDA) levels (WMD: -0.32; 95 % CI: -0.46, -0.18). Supplementation with probiotics also significantly reduced insulin (WMD: -3.02; 95 % CI: -3.88, -2.15) and homeostatic model assessment for insulin resistance (HOMA-IR) (WMD: -0.71; 95 % CI: -0.89, -0.52). Probiotics significantly reduced triglycerides (WMD: -18.38; 95 % CI: -25.50, -11.26) and VLDL-cholesterol (WMD: -3.16; 95 % CI: -4.53, -1.79), while they increased HDL-cholesterol levels (WMD: 1.52; 95 % CI: 0.29, 2.75). CONCLUSION This meta-analysis demonstrated that taking probiotic by patients with neurological disorders had beneficial effects on CRP, MDA, insulin, HOMA-IR, triglycerides, VLDL-cholesterol and HDL-cholesterol levels, but did not affect other metabolic parameters.
-
3.
Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproterone acetate with third generation progestins.
Amiri, M, Ramezani Tehrani, F, Nahidi, F, Kabir, A, Azizi, F, Carmina, E
Metabolism: clinical and experimental. 2017;:22-35
Abstract
BACKGROUND Although oral contraceptives (OCs) are the most common treatment in women with polycystic ovary syndrome (PCOS), their effects and safety on the metabolic profiles of these patients are relatively unknown. In this meta-analysis the effects of the different durations (from 3months to 1year) of OC treatment using cyproterone acetate (CA) or third generation progestins on metabolic profile of patients with PCOS were assessed. MATERIALS AND METHODS PubMed, Scopus, Google Scholar and ScienceDirect databases (2001-2015) were searched to identify clinical trials investigating the effects of OC containing CA or third generation progestins on metabolic profiles of women with PCOS. Both fixed and random effect models were used. Subgroup analyses were performed based on the progestin compounds used and on duration of treatment. RESULTS Oral contraceptive (OC) use was found to be associated with a worsening in lipid profiles but no changes were observed in other metabolic outcomes, including body mass index (BMI), fasting blood glucose (FBG), fasting insulin, homeostatic model for measuring insulin resistance (HOMA-IR) and in blood pressure (BP) values. All studied OCs showed similar effects on lipid profiles but with different timings, with products containing CA, requiring 6months to raise high density lipoprotein-cholesterol (HDL-C) levels and 12months to increase triglycerides (TG). On the contrary, products containing drospirenone (DRSP) or desogestrel (DSG) increased HDL-C after only 3months but determined elevations of TG after 6months. All OCs induced an increase in low density lipoprotein-cholesterol (LDL-C) after 12months of use. CONCLUSIONS The study shows that, in women with PCOS, OC use is associated with significant changes in lipid profiles, including elevation not only in HDL-C but also in TG and LDL-C. All OCs studied showed similar effects but with different timings, with products containing CA generally requiring more prolonged use to increase serum lipids. Instead, OC use does not affect body weight, BP or glucose levels, with only some minor increase of fasting insulin levels.
-
4.
Metabolome-wide association study identified the association between a circulating polyunsaturated fatty acids variant rs174548 and lung cancer.
Wang, C, Qin, N, Zhu, M, Chen, M, Xie, K, Cheng, Y, Dai, J, Liu, J, Xia, Y, Ma, H, et al
Carcinogenesis. 2017;(11):1147-1154
-
-
Free full text
-
Abstract
Quantitative trait loci (QTLs) are widely used as instruments to infer causal risk factors of diseases based on the idea of mendelian randomization. Plasma metabolites can serve as risk factors of cancer, and the heritability of many circulating metabolites was high. We conducted a metabolome-wide association study (MWAS) to systematically investigate the effects of genetic variants on metabolites and lung cancer based on published genome-wide association study (GWASs) and metabolic-QTL (mQTL) study. Then we confirmed the results by subsequent genetic and metabolic validations and inferred the causal relationship between identified metabolites and lung cancer through genetic variant(s). We firstly identified six polyunsaturated fatty acids (PUFAs) represented by rs174548-linked haplotype were significantly associated with lung cancer risk in a Chinese GWAS (2311 cases and 3077 controls). Rs174548 was further confirmed to be associated with lung cancer in 13 821 Europeans and 18 471 Asians (ORmeta = 0.87, Pmeta = 1.76 × 10-15) and the effect was much stronger in females (Pinteraction = 6.00 × 10-4). We next validated rs174548-plasma PUFA association in 253 Chinese subjects (β = -0.57, P = 1.68 × 10-3). Rs174548 was also found associated with FADS1 (the major fatty acid desaturase of identified PUFAs) expression in liver tissues. Taken together, we found that rs174548 was associated with both PUFAs and lung cancer. Because rs174548 was the only mQTL variant of PUFAs reported by previous GWASs and explained a large proportion of heritability, we proposed that plasma PUFAs could be causally associated with lung cancer based on the idea of mendelian randomization. These findings provide a diet-related risk factor and may have important implications for prevention on lung cancer.